Study details
Enrolling now
A Phase 1 Trial of Belzupacap Sarotalocan (AU-011)
Aura Biosciences
NCT IDNCT05483868ClinicalTrials.gov data as of Apr 2026
Phase
Phase 1
Target enrollment
55
Study length
about 4.5 years
Ages
18+
Locations
11 sites in AR, CA, NY +3
What this study is about
This trial is testing the safety and feasibility of a new treatment called AU-011 for bladder cancer. The treatment involves injections with or without laser application, administered to adults.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take AU-011
- 2.Take AU-011 in Combination with Medical Laser Administration
- 3.Take AU-011 in Combination with Medical Laser Adminstration
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Standard
How treatment is administered
Treatment Assignment
All receive treatment
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Endpoints
Primary: Safety of AU-011: Incidences of SAEs and DLTs
Secondary: Complete response (CR) rate, Durable CR rate, Duration of response (DoR), Recurrence-free survival (RFS)
Devices
therapeutic
Body systems
Oncology